CL2020002868A1 - Compuestos de azabencimidazol y productos farmacéuticos. - Google Patents
Compuestos de azabencimidazol y productos farmacéuticos.Info
- Publication number
- CL2020002868A1 CL2020002868A1 CL2020002868A CL2020002868A CL2020002868A1 CL 2020002868 A1 CL2020002868 A1 CL 2020002868A1 CL 2020002868 A CL2020002868 A CL 2020002868A CL 2020002868 A CL2020002868 A CL 2020002868A CL 2020002868 A1 CL2020002868 A1 CL 2020002868A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- bladder
- pharmaceuticals
- pam
- present
- Prior art date
Links
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 abstract 3
- 208000004168 Underactive Urinary Bladder Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 abstract 1
- 206010029279 Neurogenic bladder Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000027939 micturition Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
El propósito de la presente invención es proporcionar compuestos que tengan una acción M3 PAM. Ejemplos de la presente invención incluyen compuestos de azabencimidazol representados, por ejemplo, por la fórmula [I] y sus sales farmacológicamente aceptables. Estos compuestos tienen actividad M3 PAM. Además, debido a que estos compuestos tienen actividad M3 PAM, estos compuestos son útiles como agentes para la prevención o tratamiento de trastornos de micción y/o almacenamiento en vejiga hipoactiva, vejiga hipotónica, vejiga contráctil, subactividad del detrusor y vejiga neurogénica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018089867 | 2018-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002868A1 true CL2020002868A1 (es) | 2021-04-16 |
Family
ID=68467433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002868A CL2020002868A1 (es) | 2018-05-08 | 2020-11-05 | Compuestos de azabencimidazol y productos farmacéuticos. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US12319683B2 (es) |
| EP (1) | EP3792260B1 (es) |
| JP (1) | JP7235047B2 (es) |
| KR (1) | KR102819951B1 (es) |
| CN (1) | CN112368282B (es) |
| AU (1) | AU2019265134B2 (es) |
| BR (1) | BR112020022662A2 (es) |
| CA (1) | CA3099655A1 (es) |
| CL (1) | CL2020002868A1 (es) |
| CO (1) | CO2020013848A2 (es) |
| DK (1) | DK3792260T3 (es) |
| EC (1) | ECSP20078586A (es) |
| ES (1) | ES2992256T3 (es) |
| FI (1) | FI3792260T3 (es) |
| HR (1) | HRP20241414T1 (es) |
| HU (1) | HUE068695T2 (es) |
| IL (1) | IL278517B2 (es) |
| LT (1) | LT3792260T (es) |
| MA (1) | MA52587B1 (es) |
| MD (1) | MD3792260T2 (es) |
| MX (1) | MX2020011855A (es) |
| MY (1) | MY202833A (es) |
| PE (1) | PE20211384A1 (es) |
| PH (1) | PH12020551873A1 (es) |
| PL (1) | PL3792260T3 (es) |
| PT (1) | PT3792260T (es) |
| RS (1) | RS65996B1 (es) |
| SA (1) | SA520420487B1 (es) |
| SG (1) | SG11202011003TA (es) |
| SI (1) | SI3792260T1 (es) |
| SM (1) | SMT202400407T1 (es) |
| TW (1) | TWI868068B (es) |
| UA (1) | UA126774C2 (es) |
| WO (1) | WO2019216294A1 (es) |
| ZA (1) | ZA202007164B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068695T2 (hu) | 2018-05-08 | 2025-01-28 | Nippon Shinyaku Co Ltd | Azabenzimidazol vegyületek és gyógyszerek |
| PH12022551134A1 (en) | 2019-11-13 | 2023-07-31 | Nippon Shinyaku Co Ltd | Therapeutic agent and prophylactic agent for functional gastrointestinal disorders and xerostomia |
| US12528813B2 (en) | 2019-11-13 | 2026-01-20 | Nippon Shinyaku Co., Ltd. | Substituted imidazo[4,5-b]pyridines as M3 receptor PAMs |
| CN118045050B (zh) * | 2023-11-16 | 2025-06-10 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种头颈部放疗患者适用的缓解口腔干燥的组合物及其制备方法 |
| WO2025153078A1 (zh) * | 2024-01-17 | 2025-07-24 | 盛睿泽华医药科技（苏州）有限公司 | 可溶性环氧水解酶抑制剂及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571819A (en) | 1994-11-22 | 1996-11-05 | Sabb; Annmarie L. | Imidazopyridines as muscarinic agents |
| NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| TW200538095A (en) | 2004-03-11 | 2005-12-01 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
| WO2005087763A1 (en) | 2004-03-11 | 2005-09-22 | Theravance, Inc. | Diphenylmethyl compounds useful as muscarinic receptor antagonists |
| US20080015196A1 (en) | 2004-04-16 | 2008-01-17 | Neurogen Corporation | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| CN101490037B (zh) | 2006-07-11 | 2013-06-12 | 大熊制药株式会社 | 联芳基苯并咪唑衍生物以及包含该衍生物的药物组合物 |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| NZ586399A (en) * | 2008-01-24 | 2011-12-22 | Ucb Pharma Sa | Compounds comprising a cyclobutoxy group |
| MX2011011937A (es) | 2009-05-11 | 2012-01-27 | Ratiopharm Gmbh | Desfesoterodina en la forma de una sal del acido tartarico. |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| JP5667934B2 (ja) | 2010-06-28 | 2015-02-12 | 大日本住友製薬株式会社 | 新規２環性複素環化合物からなる医薬 |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| CN103429591A (zh) | 2010-12-17 | 2013-12-04 | 拜耳知识产权有限责任公司 | 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪 |
| CA2821819A1 (en) * | 2010-12-17 | 2012-06-21 | Marcus Koppitz | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| SG11201400102WA (en) | 2011-08-24 | 2014-03-28 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| JP2013237634A (ja) | 2012-05-14 | 2013-11-28 | Dainippon Sumitomo Pharma Co Ltd | 縮環イミダゾロン誘導体 |
| GB201302927D0 (en) * | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| CN106414438B (zh) | 2014-06-06 | 2019-12-31 | 安斯泰来制药株式会社 | 2-酰氨基噻唑衍生物或其盐 |
| TR201908031T4 (tr) | 2014-08-26 | 2019-06-21 | Astellas Pharma Inc | İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu. |
| HK1245646A1 (zh) | 2015-04-28 | 2018-08-31 | 安斯泰来制药有限公司 | 口服给药用医药组合物 |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018157856A1 (zh) | 2017-03-03 | 2018-09-07 | 江苏豪森药业集团有限公司 | 酰胺类衍生物抑制剂及其制备方法和应用 |
| EP3730141A4 (en) | 2017-12-21 | 2021-10-13 | Kyorin Pharmaceutical Co., Ltd. | THERAPEUTIC FOR NIGHTLY POLLAKISURIA |
| WO2019189766A1 (ja) | 2018-03-30 | 2019-10-03 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| HUE068695T2 (hu) | 2018-05-08 | 2025-01-28 | Nippon Shinyaku Co Ltd | Azabenzimidazol vegyületek és gyógyszerek |
| PH12022551134A1 (en) | 2019-11-13 | 2023-07-31 | Nippon Shinyaku Co Ltd | Therapeutic agent and prophylactic agent for functional gastrointestinal disorders and xerostomia |
| US12528813B2 (en) | 2019-11-13 | 2026-01-20 | Nippon Shinyaku Co., Ltd. | Substituted imidazo[4,5-b]pyridines as M3 receptor PAMs |
-
2019
- 2019-05-07 HU HUE19800286A patent/HUE068695T2/hu unknown
- 2019-05-07 SM SM20240407T patent/SMT202400407T1/it unknown
- 2019-05-07 ES ES19800286T patent/ES2992256T3/es active Active
- 2019-05-07 US US17/053,380 patent/US12319683B2/en active Active
- 2019-05-07 KR KR1020207035176A patent/KR102819951B1/ko active Active
- 2019-05-07 MY MYPI2020005795A patent/MY202833A/en unknown
- 2019-05-07 PE PE2020001816A patent/PE20211384A1/es unknown
- 2019-05-07 PT PT198002867T patent/PT3792260T/pt unknown
- 2019-05-07 SI SI201930830T patent/SI3792260T1/sl unknown
- 2019-05-07 WO PCT/JP2019/018201 patent/WO2019216294A1/ja not_active Ceased
- 2019-05-07 FI FIEP19800286.7T patent/FI3792260T3/fi active
- 2019-05-07 EP EP19800286.7A patent/EP3792260B1/en active Active
- 2019-05-07 IL IL278517A patent/IL278517B2/en unknown
- 2019-05-07 UA UAA202007681A patent/UA126774C2/uk unknown
- 2019-05-07 RS RS20241035A patent/RS65996B1/sr unknown
- 2019-05-07 JP JP2020518289A patent/JP7235047B2/ja active Active
- 2019-05-07 CA CA3099655A patent/CA3099655A1/en active Pending
- 2019-05-07 AU AU2019265134A patent/AU2019265134B2/en active Active
- 2019-05-07 DK DK19800286.7T patent/DK3792260T3/da active
- 2019-05-07 BR BR112020022662-9A patent/BR112020022662A2/pt unknown
- 2019-05-07 SG SG11202011003TA patent/SG11202011003TA/en unknown
- 2019-05-07 MD MDE20210245T patent/MD3792260T2/ro active IP Right Revival
- 2019-05-07 MA MA52587A patent/MA52587B1/fr unknown
- 2019-05-07 HR HRP20241414TT patent/HRP20241414T1/hr unknown
- 2019-05-07 MX MX2020011855A patent/MX2020011855A/es unknown
- 2019-05-07 CN CN201980046177.6A patent/CN112368282B/zh active Active
- 2019-05-07 PL PL19800286.7T patent/PL3792260T3/pl unknown
- 2019-05-07 LT LTEPPCT/JP2019/018201T patent/LT3792260T/lt unknown
- 2019-05-08 TW TW108115846A patent/TWI868068B/zh active
-
2020
- 2020-11-05 CL CL2020002868A patent/CL2020002868A1/es unknown
- 2020-11-05 SA SA520420487A patent/SA520420487B1/ar unknown
- 2020-11-05 CO CONC2020/0013848A patent/CO2020013848A2/es unknown
- 2020-11-05 PH PH12020551873A patent/PH12020551873A1/en unknown
- 2020-11-17 ZA ZA2020/07164A patent/ZA202007164B/en unknown
- 2020-12-07 EC ECSENADI202078586A patent/ECSP20078586A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013848A2 (es) | Compuestos de azabencimidazol y productos farmacéuticos | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| MX2019004616A (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
| CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
| BR112016029853A2 (pt) | compostos de indazol substituído como inibidores de irak4 | |
| CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| NI201500120A (es) | Compuestos de biaril - amida como inhibidores de cinasa | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| UY36342A (es) | Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos | |
| BR112018000635A2 (pt) | compostos aza substituídos como inibidores irak-4 | |
| BR112018000624A2 (pt) | compostos de indazol e azaindazol como inibidores de irak-4 | |
| ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| CU24335B1 (es) | Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer | |
| NI201400102A (es) | Derivados macrocíclicos para el tratamiento de enfermedades proliferativas | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| CU20130126A7 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| CU20160195A7 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CU20160166A7 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| BR112018012292A2 (pt) | compostos e composições tricíclicos como inibidores de cinase |